Zealand Pharma A/s

Other

Wyeth

Eddi Meier

Ditte Riber

Jens Rosengren Daugaard

Bjarne Due Larsen

Marie Skovgaard

Jakob Lind Tolborg

Keld Fosgerau

Trine Skovlund Ryge Neerup

Peter Holme Jensen

Jørgen Søberg Petersen

Camilla Ærteberg Bæk

James B Martins

Morten Schak Nielsen

Niklas Rye Jorgensen

Anne Louise Kjolbye

Gita Kampen

Eva Steiness

Soren Neve

Niels-Henrik Holstein-Rathlou

Jorgen Soberg Petersen

Morten Schak Neilsen

Neils-Henrik Holstein-Rathlou

Lars Bo Laurenborg Hansen

Trine Skovlund Ryge

Anne Louise Kjoelbye

Henrik Duelund Pedersen

Rie Schultz Hansen

Lene Axelsen

Camilla ÆRteberg BÆK

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Acylated glucagon analogues

The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the glucagon-like peptide-1 (GLP-1) receptor as compared to human glucagon.

Glucagon analogues

The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon.

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Disclosed are novel peptides including antiarrhythmic peptides that have improved stability. Further disclosed are compositions that include such peptides and methods of using the compositions particularly as medicaments.

Antiarrhythmic peptides

Medical uses of intercellular communication facilitating compounds

Disclosed are compositions and methods for modulating hemichannel function in a cell, tissue or organ. The invention also relates to useful screens for detecting such compounds, particularly those capable of modulating connexin phosphorylation. Further provided are therapeutic methods for preventing or treating conditions impacted by undesired hemichannel function in a mammal such as heart arrhythmia.

Compositions and methods for modulating connexin hemichannels

Growing community of inventors

Vaerløse, Denmark

Eddi Meier